This is the third high-profile resignation within a week of the controversial approval of Biogen's Alzheimer's disease (AD) medication by the U.S. FDA, which has been described as a "dangerous...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)